Cellular Biomedicine Group Hk Limited

Cellular Biomedicine Group, Inc.

Huawei Technologies Co., Limited

Abelzeta Inc.

Yanfeng Li

Yutian Wei

Xin Yao

Yihong Yao

Jiaqi Huang

Shigui Zhu

Lin Zhu

Li Zhang

Wei Zhu

Qingxia Wang

Jiaping He

Anyun Ma

Zhiyuan Li

Yongbing Gao

Xun Wang

Fang Liu

Xiaoteng Lv

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof

The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.

BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof

A power supply system includes at least one inverter, at least one cell string, and a transformer, where an input end of the at least one inverter is connected to an output end of the at least one cell string, an output end of the at least one inverter is connected to an input end of the transformer, and an output end of the transformer is configured to output a power supply voltage. The output end of the at least one inverter is connected to an output end of an inverter unit.

Power supply system and power supply method

Growing community of inventors

Hong Kong, China

Yanfeng Li